June 1, 2024Open Access

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect

Key Points

Key points are not available for this paper at this time.

Abstract

The dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor immune microenvironment (TME) plays a crucial role in the therapeutic trajectory of non-small cell lung cancer (NSCLC). Understanding the functional dynamics and resistance mechanisms of TKIs is essential for advancing the treatment of NSCLC.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Lu et al. (Sat,) studied this question.

synapsesocial.com/papers/68e669a9b6db6435875f5865 https://doi.org/https://doi.org/10.1136/jitc-2024-009165

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models2023 · 43 citations
2Targeted Therapies to Improve Tumor Immunotherapy2008 · 117 citations
3Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment2022 · 143 citations
4Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer2018 · 825 citations
5Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy2021 · 83 citations

AI에게 질문

Bookmark

View Full Paper